Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Adicet Bio Inc (ACET)

Adicet Bio Inc (ACET)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 74,985
  • Shares Outstanding, K 82,401
  • Annual Sales, $ 0 K
  • Annual Income, $ -142,660 K
  • EBIT $ -128 M
  • EBITDA $ -103 M
  • 60-Month Beta 1.88
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.34
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.71
  • Most Recent Earnings $-0.34 on 11/06/24
  • Next Earnings Date 11/13/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 230.35% ( +26.31%)
  • Historical Volatility 81.96%
  • IV Percentile 81%
  • IV Rank 37.05%
  • IV High 608.42% on 04/22/24
  • IV Low 7.83% on 09/16/24
  • Put/Call Vol Ratio 0.19
  • Today's Volume 124
  • Volume Avg (30-Day) 75
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 1,779
  • Open Int (30-Day) 1,589

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.37
  • Number of Estimates 4
  • High Estimate -0.36
  • Low Estimate -0.38
  • Prior Year -0.69
  • Growth Rate Est. (year over year) +46.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8100 +12.35%
on 12/19/24
1.1900 -23.53%
on 12/02/24
-0.0571 (-5.90%)
since 11/20/24
3-Month
0.8100 +12.35%
on 12/19/24
1.5400 -40.91%
on 10/22/24
-0.6200 (-40.52%)
since 09/20/24
52-Week
0.8100 +12.35%
on 12/19/24
3.7700 -75.86%
on 01/09/24
-0.5500 (-37.67%)
since 12/20/23

Most Recent Stories

More News
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on April...

ACET : 0.9100 (+5.78%)
Adicet Bio to Participate in 2023 Canaccord Genuity Horizons in Oncology Virtual Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief...

ACET : 0.9100 (+5.78%)
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on March...

ACET : 0.9100 (+5.78%)
Adicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights...

ACET : 0.9100 (+5.78%)
Adicet Bio to Participate in 2023 Jefferies Biotech on the Bay Summit

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief...

ACET : 0.9100 (+5.78%)
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on February...

ACET : 0.9100 (+5.78%)
Adicet Bio to Participate in a Fireside Chat at the 2023 Guggenheim Oncology Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief...

ACET : 0.9100 (+5.78%)
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on January...

ACET : 0.9100 (+5.78%)
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on December...

ACET : 0.9100 (+5.78%)
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced positive safety and efficacy data...

ACET : 0.9100 (+5.78%)

Business Summary

Adicet Bio Inc. is a biotechnology company. It engages in discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet Bio Inc., formerly known as RESTORBIO INC, is based in Calif.

See More

Key Turning Points

3rd Resistance Point 0.9885
2nd Resistance Point 0.9528
1st Resistance Point 0.9314
Last Price 0.9100
1st Support Level 0.8743
2nd Support Level 0.8386
3rd Support Level 0.8172

See More

52-Week High 3.7700
Fibonacci 61.8% 2.6393
Fibonacci 50% 2.2900
Fibonacci 38.2% 1.9407
Last Price 0.9100
52-Week Low 0.8100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar